What is your approach to patients who experience widespread progression on EGFR inhibitors found to have MET amplification on tumor biopsy in addition to sensitizing EGFR mutation?  


Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice